Fig 1: The functional and pathway enrichment from PAH patients with high TFRC and diagnostic power of TFRC. (A) The GSEA analysis showing biological processes enriched in high TFRC group versus low TFRC group in training dataset. (B) The KEGG analysis displaying biological pathways enriched in high TFRC group versus low TFRC group in training dataset. (C) The ROC curve of validation cohort in dataset GSE53408, (D) The ROC curve of validation cohort in dataset GSE22356.
Fig 2: Validation of TFRC in clinical specimens. (A) TFRC expression in clinical serum samples. (B) Diagnostic performance of serums TFRC in PAH in ROC curve analysis. *P < 0.05 compared to control, as analyzed by unpaired t test
Fig 3: Establishment of MCT induced PH mouse model. (A) RVSP and (B) RV/(LV + S) were assessed in MCT-induced PH rats or control (n = 8/group). (C) Representative images of H&E and EVG staining of lung tissues in two group. Black asterisk indicates lumen of pulmonary artery. Scale bar = 30 mm. (D) Quantification of media thickness of small pulmonary arterioles (E) The mRNA expression level of TFRC relative to GAPDH were examined in lung tissues from MCT-induced PH mice or control. (n = 5/group). (F) Representative Western blots and quantification of TFRC and GAPDH in the lungs of MCT- induced rats and controls. RVSP = right ventricular systematic pressure; RV/(LV + S) = right ventricular/(left ventricular + septum). Data represent mean ± SEM. *P < 0.05; **P < 0.01 compared to control, as analyzed by unpaired t test or Mann-Whitney test as appropriate
Supplier Page from Abcam for Human Transferrin Receptor ELISA Kit (CD71)